InventisBio of Shanghai Raises $19 Million from OrbiMed and Lilly

01:00 EDT 1 Jun 2017 | ChinaBio Today

InventisBio, a Shanghai-US startup, raised $19 million in a Series B round for its portfolio of four small molecule candidates. The two-year-old company is targeting cancer (lung and breast) and gout indications, developing molecules that might be paired with immuno-oncology therapies. It hopes to start clinical trials on three of the candidates in the US and China this year. The investment was led by OrbiMed Asia Partners and joined by Lilly Asia Ventures. More details....

Share this with colleagues:  

Original Article: InventisBio of Shanghai Raises $19 Million from OrbiMed and Lilly


More From BioPortfolio on "InventisBio of Shanghai Raises $19 Million from OrbiMed and Lilly"

Quick Search

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...